SOLODYN® (MINOCYCLINE HCl, USP) EXTENDED RELEASE TABLETS

SOLODYN - minocycline hydrochloride tablet, film coated, extended release 
Medicis Pharmaceutical Corp.

----------

SOLODYN®
(MINOCYCLINE HCl, USP)
EXTENDED RELEASE TABLETS

Rx Only

KEEP OUT OF REACH OF CHILDREN

To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SOLODYN® should be used only as indicated.

SOLODYN® is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris.

This formulation of minocycline has not been evaluated in the treatment of infections.

DESCRIPTION

Minocycline hydrochloride, a semi synthetic derivative of tetracycline, is [4S-(4α,4aα,5aα,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono hydrochloride. The structural formula is represented below:

Chemical Structure

C23H27N3O7•HCl             M. W. 493.95

SOLODYN® Tablets for oral administration contain minocycline hydrochloride USP equivalent to 45 mg, 65 mg, 90 mg, 115 mg, or 135 mg of minocycline. In addition, 45 mg, 65 mg, 90 mg, 115 mg, and 135 mg tablets contain the following inactive ingredients: lactose monohydrate NF, hypromellose type 2910 USP, magnesium stearate NF, colloidal silicon dioxide NF, and carnauba wax NF. The 45 mg tablets also contain opadry II gray which contains: lactose monohydrate NF, hypromellose type 2910 USP, titanium dioxide USP, triacetin USP, and iron oxide black JPE. The 65 mg tablets also contain opadry II blue which contains: hypromellose type 2910 USP, lactose monohydrate NF, FD&C Blue #1, polyethylene glycol 3350 NF, FD&C Blue #2, titanium dioxide USP, triacetin USP, and D&C Yellow #10. The 90 mg tablets also contain opadry II yellow which contains: hypromellose type 2910 USP, lactose monohydrate NF, titanium dioxide USP, iron oxide yellow NF, polyethylene glycol 3350 NF, and triacetin USP. The 115 mg tablets also contain opadry II green which contains: hypromellose type 2910 USP, lactose monohydrate NF, D&C yellow #10, triacetin USP, FD&C Blue #1, titanium dioxide USP, and FD&C Blue #2. The 135 mg tablets also contain opadry II pink which contains: hypromellose type 2910 USP, lactose monohydrate NF, titanium dioxide USP, polyethylene glycol 3350 NF, iron oxide red NF, and triacetin USP.

CLINICAL PHARMACOLOGY

Pharmacokinetics

SOLODYN® Tablets are not bioequivalent to minocycline products. Based on pharmacokinetic studies in healthy adults, SOLODYN® Tablets produce a delayed Tmax at 3.5–4.0 hours as compared to a non-modified release reference minocycline product (Tmax at 2.25–3 hours). At steady-state (Day 6), the mean AUC(0–24) and Cmax were 33.32 µg×hr/mL and 2.63 µg/mL for SOLODYN® Tablets and 46.35 µg×hr/mL and 2.92 µg/mL for Minocin® capsules, respectively. These parameters are based on dose adjusted to 135 mg per day for both products.

A single-dose, four-way crossover study demonstrated that all strengths of SOLODYN® Tablets (45 mg, 90 mg, and 135 mg) exhibited dose-proportional pharmacokinetics.

When SOLODYN® Tablets were administered concomitantly with a meal that included dairy products, the extent and timing of absorption of minocycline did not differ from that of administration under fasting conditions.

Microbiology

Minocycline is bacteriostatic exerting its antimicrobial effect by the inhibition of bacterial protein synthesis. Minocycline is lipid soluble and distributes in to the skin and sebum. Minocycline has been shown to have in vitro activity against Propionibacterium acnes, an organism associated with acne vulgaris, however, the clinical significance of this activity against P. acnes in patients with acne vulgaris is not known.

CLINICAL STUDIES

The safety and efficacy of SOLODYN® in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris was assessed in two 12-week, multi-center, randomized, double-blind, placebo-controlled, studies in subjects ≥ 12 years. The mean age of subjects was 20 years and subjects were from the following racial groups: White (73%), Hispanic (13%), Black (11%), Asian/Pacific Islander (2%), and Other (2%).

In two efficacy and safety trials, a total of 924 subjects with non-nodular moderate to severe acne vulgaris received SOLODYN® or placebo for a total of 12 weeks, according to the following dose assignments.

Subject's Weight (lbs.)Subject's Weight (kg)Available Caplet Strength (mg)Actual mg/kg Dose
99 – 13145.00 – 59.54451.00 – 0.76
132 – 19960.00 – 90.45 90 1.50 – 1.00
200 – 30090.91 – 136.361351.48 – 0.99

The two primary efficacy endpoints were:

1)
Mean percent change in inflammatory lesion counts from Baseline to 12 weeks.
2)
Percentage of subjects with an Evaluator's Global Severity Assessment (EGSA) of clear or almost clear at 12 weeks.

Efficacy results are presented in Table 1.

Table 1 – Efficacy Results at Week 12
Study 1Study 2
SOLODYN®
(1 mg/kg)
N = 300
Placebo
N = 151
SOLODYN®
(1 mg/kg)
N = 315
Placebo
N = 158
*
Evaluator's Global Severity Assessment
Mean Percent Improvement in Inflammatory Lesions43.1%31.7%45.8%30.8%
No. (%) of Subjects Clear or Almost Clear on the EGSA*52 (17.3%)12 (7.9%)50 (15.9%)15 (9.5%)

SOLODYN® did not demonstrate any effect on non-inflammatory lesions (benefit or worsening).

INDICATIONS AND USAGE

SOLODYN® is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. SOLODYN® did not demonstrate any effect on non-inflammatory lesions. Safety of SOLODYN® has not been established beyond 12 weeks of use.

This formulation of minocycline has not been evaluated in the treatment of infections.

To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SOLODYN® should be used only as indicated.

CONTRAINDICATIONS

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

WARNINGS

Teratogenic effects

1) MINOCYCLINE, LIKE OTHER TETRACYCLINE-CLASS ANTIBIOTICS, CAN CAUSE FETAL HARM WHEN ADMINISTERED TO A PREGNANT WOMAN. IF ANY TETRACYCLINE IS USED DURING PREGNANCY OR IF THE PATIENT BECOMES PREGNANT WHILE TAKING THESE DRUGS, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS.

SOLODYN® should not be used during pregnancy nor by individuals of either gender who are attempting to conceive a child (see PRECAUTIONS: Impairment of Fertility & Pregnancy).

2) THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD UP TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN).

This adverse reaction is more common during long-term use of the drug but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED DURING TOOTH DEVELOPMENT.

3) All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued.

Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can cause retardation of skeletal development on the developing fetus. Evidence of embryotoxicity has been noted in animals treated early in pregnancy (see PRECAUTIONS: Pregnancy section).

Gastro-intestinal effects

1. Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of "antibiotic-associated colitis".

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against Clostridium difficile colitis.

2. Hepatotoxicity – Post-marketing cases of serious liver injury, including irreversible drug-induced hepatitis and fulminant hepatic failure (sometimes fatal) have been reported with minocycline use in the treatment of acne.

Metabolic effects

The anti-anabolic action of the tetracyclines may cause an increase in BUN. While this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline-class antibiotics may lead to azotemia, hyperphosphatemia, and acidosis. If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity. Under such conditions, lower than usual total doses are indicated, and if therapy is prolonged, serum level determinations of the drug may be advisable.

Central nervous system effects

1. Central nervous system side effects including light-headedness, dizziness or vertigo have been reported with minocycline therapy. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. These symptoms may disappear during therapy and usually rapidly disappear when the drug is discontinued.

2. Pseudotumor cerebri (benign intracranial hypertension) in adults and adolescents has been associated with the use of tetracyclines. Minocycline has been reported to cause or precipitate pseudotumor cerebri, the hallmark of which is papilledema. Clinical manifestations include headache and blurred vision. Bulging fontanels have been associated with the use of tetracyclines in infants. Although signs and symptoms of pseudotumor cerebri resolve after discontinuation of treatment, the possibility for permanent sequelae such as visual loss that may be permanent or severe exists. Patients should be questioned for visual disturbances prior to initiation of treatment with tetracyclines and should be routinely checked for papilledema while on treatment.

Concomitant use of isotretinoin and minocycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri.

Photosensitivity

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. This has been reported rarely with minocycline. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using minocycline. If patients need to be outdoors while using minocycline, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician.

PRECAUTIONS

General

Safety of SOLODYN® beyond 12 weeks of use has not been established.

As with other antibiotic preparations, use of SOLODYN® may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, the antibiotic should be discontinued and appropriate therapy instituted.

Bacterial resistance to the tetracyclines may develop in patients using SOLODYN,® therefore the susceptibility of bacteria associated with infection should be considered in selecting antimicrobial therapy. Because of the potential for drug-resistant bacteria to develop during the use of SOLODYN,® it should be used only as indicated.

Autoimmune Syndromes

Tetracyclines have been associated with the development of autoimmune syndromes. The long-term use of minocycline in the treatment of acne has been associated with drug-induced lupus-like syndrome, autoimmune hepatitis and vasculitis. Sporadic cases of serum sickness have presented shortly after minocycline use. Symptoms may be manifested by fever, rash, arthralgia, and malaise. In symptomatic patients, liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients. Use of all tetracycline-class drugs should be discontinued immediately.

Serious Skin/Hypersensitivity Reaction

Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with minocycline use in treatment of acne.

Tissue Hyperpigmentation

Tetracycline class antibiotics are known to cause hyperpigmentation. Tetracycline therapy may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. Skin and oral pigmentation has been reported to occur independently of time or amount of drug administration, whereas other tissue pigmentation has been reported to occur upon prolonged administration. Skin pigmentation includes diffuse pigmentation as well as over sites of scars or injury.

Information for Patients

(See Patient Package Insert that accompanies this Package Insert for additional information to give patients)

  1. Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines, including minocycline. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using minocycline. If patients need to be outdoors while using minocycline, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. Treatment should be discontinued at the first evidence of skin erythema.
  2. Patients who experience central nervous system symptoms (see WARNINGS) should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. Patients should also be cautioned about seeking medical help for headaches or blurred vision.
  3. Concurrent use of tetracycline may render oral contraceptives less effective (See Drug Interactions).
  4. Autoimmune syndromes, including drug-induced lupus-like syndrome, autoimmune hepatitis, vasculitis and serum sickness have been observed with tetracycline-class antibiotics, including minocycline. Symptoms may be manifested by arthralgia, fever, rash and malaise. Patients who experience such symptoms should be cautioned to stop the drug immediately and seek medical help.
  5. Patients should be counseled about discoloration of skin, scars, teeth or gums that can arise from minocycline therapy.
  6. Take SOLODYN® exactly as directed. Skipping doses or not completing the full course of therapy may decrease the effectiveness of the current treatment course and increase the likelihood that bacteria will develop resistance and will not be treatable by other antibacterial drugs in the future.
  7. SOLODYN® should not be used by pregnant women or women attempting to conceive a child (See Pregnancy, Carcinogenesis and Mutagenesis sections).
  8. It is recommended that SOLODYN® not be used by men who are attempting to father a child (See Impairment of Fertility section).

Laboratory Tests

Periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies should be performed. Appropriate tests for autoimmune syndromes should be performed as indicated.

Drug Interactions

1. Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

2. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin.

3. The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.

4. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.

5. In a multi-center study to evaluate the effect of SOLODYN® on low dose oral contraceptives, hormone levels over one menstrual cycle with and without SOLODYN® 1 mg/kg once-daily were measured.

Based on the results of this trial, minocycline-related changes in estradiol, progestinic hormone, FSH and LH plasma levels, of breakthrough bleeding, or of contraceptive failure, can not be ruled out. To avoid contraceptive failure, female patients are advised to use a second form of contraceptive during treatment with minocycline.

Drug/Laboratory Test Interactions

False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

Carcinogenesis, Mutagenesis & Impairment of Fertility

Carcinogenesis

Long-term animal studies have not been performed to evaluate the carcinogenic potential of minocycline. A structurally related compound, oxytetracycline, was found to produce adrenal and pituitary tumors in rats.

Mutagenesis

Minocycline was not mutagenic in vitro in a bacterial reverse mutation assay (Ames test) or CHO/HGPRT mammalian cell assay in the presence or absence of metabolic activation. Minocycline was not clastogenic in vitro using human peripheral blood lymphocytes or in vivo in a mouse micronucleus test.

Impairment of Fertility

Male and female reproductive performance in rats was unaffected by oral doses of minocycline of up to 300 mg/kg/day (which resulted in up to approximately 40 times the level of systemic exposure to minocycline observed in patients as a result of use of SOLODYN®). However, oral administration of 100 or 300 mg/kg/day of minocycline to male rats (resulting in approximately 15 to 40 times the level of systemic exposure to minocycline observed in patients as a result of use of SOLODYN®) adversely affected spermatogenesis. Effects observed at 300 mg/kg/day included a reduced number of sperm cells per gram of epididymis, an apparent reduction in the percentage of sperm that were motile, and (at 100 and 300 mg/kg/day) increased numbers of morphologically abnormal sperm cells. Morphological abnormailities observed in sperm samples included absent heads, misshapen heads, and abnormal flagella.

Limited human studies suggest that minocycline may have a deleterious effect on spermatogenesis.

SOLODYN® should not be used by individuals of either gender who are attempting to conceive a child.

Pregnancy

Teratogenic Effects

Pregnancy category D

(See WARNINGS)

All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. There are no adequate and well-controlled studies on the use of minocycline in pregnant women. Minocycline, like other tetracycline-class antibiotics, crosses the placenta and may cause fetal harm when administered to a pregnant woman. Rare spontaneous reports of congenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post-marketing experience. Only limited information is available regarding these reports; therefore, no conclusion on causal association can be established.

Minocycline induced skeletal malformations (bent limb bones) in fetuses when administered to pregnant rats and rabbits in doses of 30 mg/kg/day and 100 mg/kg/day, respectively, (resulting in approximately 3 times and 2 times, respectively, the systemic exposure to minocycline observed in patients as a result of use of SOLODYN®). Reduced mean fetal body weight was observed in studies in which minocycline was administered to pregnant rats at a dose of 10 mg/kg/day (which resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use SOLODYN®).

SOLODYN® should not be used during pregnancy. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and stop treatment immediately.

Nursing Mothers

Tetracycline-class antibiotics are excreted in human milk. Because of the potential for serious adverse effects on bone and tooth development in nursing infants from the tetracycline-class antibiotics, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother (see WARNINGS).

Pediatric Use

SOLODYN® is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years and older. Safety and effectiveness in pediatric patients below the age of 12 has not been established.

Use of tetracycline-class antibiotics below the age of 8 is not recommended due to the potential for tooth discoloration (see WARNINGS).

Geriatric Use

Clinical studies of SOLODYN® did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.

ADVERSE REACTIONS

Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not reflect the rates observed in practice. However, adverse reaction information from clinical trials provides a basis for identifying the adverse events that appear to be related to drug use.

Adverse events reported in clinical trials for SOLODYN® are described below in Table 2.

Table 2 – Selected Treatment-Emergent Adverse Events in at least 1% of Clinical Trial Subjects
Adverse EventSOLODYN®
(1 mg/kg)
N = 674 (%)
PLACEBO
N = 364 (%)
At least one treatment-emergent event379 (56)197 (54)
Headache152 (23)83 (23)
Fatigue62 (9)24 (7)
Dizziness59 (9)17 (5)
Pruritus31 (5)16 (4)
Malaise26 (4)9 (3)
Mood alteration17 (3)9 (3)
Somnolence13 (2)3 (1)
Urticaria10 (2)1 (0)
Tinnitus10 (2)5 (1)
Arthralgia9 (1)2 (0)
Vertigo8 (1)3 (1)
Dry mouth7 (1)5 (1)
Myalgia7 (1)4 (1)

Adverse reactions not observed in the clinical trials, but that have been reported with minocycline hydrochloride use in a variety of indications include:

Skin and hypersensitivity reactions: fixed drug eruptions, balanitis, erythema multiforme, Stevens-Johnson syndrome, anaphylactoid purpura, photosensitivity, pigmentation of skin and mucous membranes, hypersensitivity reactions, angioneurotic edema, anaphylaxis.

Autoimmune conditions: polyarthralgia, pericarditis, exacerbation of systemic lupus, pulmonary infiltrates with eosinophilia, transient lupus-like syndrome.

Central nervous system: pseudotumor cerebri, bulging fontanels in infants, decreased hearing.

Endocrine: thyroid discoloration, abnormal thyroid function.

Oncology: papillary thyroid cancer.

Oral: glossitis, dysphagia, tooth discoloration.

Gastrointestinal: enterocolitis, pancreatitis, hepatitis, liver failure.

Renal: reversible acute renal failure.

Hematology: hemolytic anemia, thrombocytopenia, eosinophilia.

Preliminary studies suggest that use of minocycline may have deleterious effects on human spermatogenesis (see Carcinogenesis, Mutagenesis, Impairment of Fertility section).

OVERDOSAGE

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Minocycline is not removed in significant quantities by hemodialysis or peritoneal dialysis.

DOSAGE AND ADMINISTRATION

The recommended dosage of SOLODYN® is approximately 1 mg/kg daily for 12 weeks. Higher doses have not shown to be of additional benefit in the treatment of inflammatory lesions of acne, and may be associated with more acute vestibular side effects.

The following table shows tablet strength and body weight to achieve approximately 1 mg/kg.

Table 3: Dosing Table for SOLODYN®
Patient's Weight (lbs.)Patient's Weight (kg)Tablet Strength (mg)Actual mg/kg Dose
99 – 12045 – 54451 – 0.83
121 – 17055 – 77651.18 – 0.84
171 – 22578 – 102901.15 – 0.88
226 – 276103 – 1251151.12 – 0.92
277 – 300126 – 1361351.07 – 0.99

SOLODYN® Tablets may be taken with or without food (see CLINICAL PHARMACOLOGY). Ingestion of food along with SOLODYN® may help reduce the risk of esophageal irritation and ulceration.

In patients with renal impairment (see WARNINGS), the total dosage should be decreased by either reducing the recommended individual doses and/or by extending the time intervals between doses.

HOW SUPPLIED

SOLODYN® (MINOCYCLINE HCl, USP) Extended Release Tablets are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 45 mg, 65 mg, 90 mg, 115 mg, or 135 mg minocycline.

The 45 mg extended release tablets are gray, unscored, coated, and debossed with "DYN-045" on one side. Each tablet contains minocycline hydrochloride equivalent to 45 mg minocycline, supplied as follows:

NDC 99207-460-30Bottle of 30
NDC 99207-460-10Bottle of 100

The 65 mg extended release tablets are blue, unscored, coated, and debossed with "DYN-065" on one side. Each tablet contains minocycline hydrochloride equivalent to 65 mg minocycline, supplied as follows:

NDC 99207-463-30Bottle of 30

The 90 mg extended release tablets are yellow, unscored, coated, and debossed with "DYN-090" on one side. Each tablet contains minocycline hydrochloride equivalent to 90 mg minocycline, supplied as follows:

NDC 99207-461-30Bottle of 30
NDC 99207-461-10Bottle of 100

The 115 mg extended release tablets are green, unscored, coated, and debossed with "DYN-115" on one side. Each tablet contains minocycline hydrochloride equivalent to 115 mg minocycline, supplied as follows:

NDC 99207-464-30Bottle of 30

The 135 mg extended release tablets are pink (orange-brown), unscored, coated, and debossed with "DYN-135" on one side. Each tablet contains minocycline hydrochloride equivalent to 135 mg minocycline, supplied as follows:

NDC 99207-462-30Bottle of 30
NDC 99207-462-10Bottle of 100

Store at 25ºC (77ºF); excursions are permitted to 15º–30ºC (59º–86ºF) [See USP Controlled Room Temperature].

Protect from light, moisture, and excessive heat.
Dispense in tight, light-resistant container with child-resistant closure.

U.S. Patent 5,908,8381 and Patents Pending

Manufactured for:
Medicis, The Dermatology Company
Scottsdale, AZ 85256

Manufactured by:
Wellspring Pharmaceutical Canada Corp.
Oakville, Ontario L6H 1M5
Canada

N4605A

17100004


1
90 mg is also covered by U.S. Patents 7,541,347 and 7,544,373

Patient Information

SOLODYN® (SO-lo-dīn) Extended Release Tablets
(minocycline HCl, USP)

Rx only

Read all patient information that comes with SOLODYN® before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of speaking with your doctor about your condition or treatment.

What is SOLODYN®?

SOLODYN® is a tetracycline-class antibiotic medicine that contains minocycline. SOLODYN® is only for the treatment of pimples and red bumps (non-nodular inflammatory lesions) that happen with moderate to severe acne in patients 12 years and older.

SOLODYN® has not been studied for use longer than 12 weeks.

SOLODYN® has not been studied for the treatment of infections.

Who should not take SOLODYN®?

Do not take SOLODYN® if you are allergic to minocycline or any other tetracycline antibiotics. Ask your doctor or pharmacist for a list of these medicines if you are not sure. See the end of this leaflet for a complete list of ingredients in SOLODYN.®

SOLODYN® should not be used by pregnant women, women attempting to conceive a child, or children up to 8 years old because:

  1. SOLODYN® may harm an unborn baby
  2. SOLODYN® may permanently turn a baby or child's teeth yellow-grey-brown during tooth development. SOLODYN® should not be used during tooth development. Tooth development happens in the last half of pregnancy and birth to age 8 years.

It is recommended that SOLODYN® not be used by men who are attempting to father a child.

What should I tell my doctor before taking SOLODYN®?

Tell your doctor about all of your medical conditions including if you:

Tell your doctor about all the other medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. SOLODYN® and other medicines may interact. Especially tell your doctor if you take:

Know the medicines you take. Keep a list of them to show your doctor and pharmacist.

How should I take SOLODYN®?

What are the possible side effects of SOLODYN®?

SOLODYN® may cause serious side effects.

Stop SOLODYN® and call your doctor if you have:

SOLODYN® may also cause:

The most common side effects with SOLODYN® include:

Call your doctor if you have a side effect that bothers you or that does not go away.

These are not all the side effects with SOLODYN.® Ask your doctor or pharmacist for more information.

How should I store SOLODYN®?

General Information about SOLODYN®

Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use SOLODYN® for a condition for which it was not prescribed. Do not give SOLODYN® to other people, even if they have the same symptoms you have. It may harm them.

This leaflet summarizes the most important information about SOLODYN.® If you would like more information, talk to your doctor. You can ask your doctor or pharmacist for information about SOLODYN® that is written for health professionals.

What are the Ingredients in SOLODYN®?

Active Ingredient: minocycline HCl USP equivalent to 45 mg, 65 mg, 90 mg, 115 mg, or 135 mg of minocycline.

Inactive Ingredients: lactose monohydrate NF, hypromellose type 2910 USP, magnesium stearate NF, colloidal silicon dioxide NF, and carnauba wax NF. The 45 mg tablets also contain opadry II gray which contains: lactose monohydrate NF, hypromellose type 2910 USP, titanium dioxide USP, triacetin USP, and iron oxide black JPE. The 65 mg tablets also contain opadry II blue which contains: hypromellose type 2910 USP, lactose monohydrate NF, FD&C Blue #1, polyethylene glycol 3350 NF, FD&C Blue #2, titanium dioxide USP, triacetin USP, and D&C Yellow #10. The 90 mg tablets also contain opadry II yellow which contains: hypromellose type 2910 USP, lactose monohydrate NF, titanium dioxide USP, iron oxide yellow NF, polyethylene glycol 3350 NF, and triacetin USP. The 115 mg tablets also contain opadry II green which contains: hypromellose type 2910 USP, lactose monohydrate NF, D&C yellow #10, triacetin USP, FD&C Blue #1, titanium dioxide USP, FD&C Blue #2. The 135 mg tablets also contain opadry II pink which contains: hypromellose type 2910 USP, lactose monohydrate NF, titanium dioxide USP, polyethylene glycol 3350 NF, iron oxide red NF, and triacetin USP.

SOLODYN® is manufactured by Wellspring Pharmaceutical Canada Corp. for Medicis, The Dermatology Company, Scottsdale, AZ, 85256.

July 2009

N4605A
17100004

PRINCIPAL DISPLAY PANEL - 45 mg Tablet Bottle Label

NDC 99207-460-30
Rx Only

45 mg*

SOLODYN®
(MINOCYCLINE HCl, USP)
EXTENDED RELEASE TABLETS

30 Tablets

PRINCIPAL DISPLAY PANEL - 45 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 65 mg Tablet Bottle Label

NDC 99207-463-30
Rx Only

65 mg*

30 TABLETS

SOLODYN®
(MINOCYCLINE HCl, USP)
EXTENDED RELEASE TABLETS

PRINCIPAL DISPLAY PANEL - 65 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 90 mg Tablet Bottle Label

NDC 99207-461-30
Rx Only

90 mg*

SOLODYN®
(MINOCYCLINE HCl, USP)
EXTENDED RELEASE TABLETS

30 Tablets

PRINCIPAL DISPLAY PANEL - 90 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 115 mg Tablet Bottle Label

NDC 99207-464-30
Rx Only

115 mg*

30 TABLETS

SOLODYN®
(MINOCYCLINE HCl, USP)
EXTENDED RELEASE TABLETS

PRINCIPAL DISPLAY PANEL - 115 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 135 mg Tablet Bottle Label

NDC 99207-462-30
Rx Only

135 mg*

SOLODYN®
(MINOCYCLINE HCl, USP)
EXTENDED RELEASE TABLETS

30 Tablets

PRINCIPAL DISPLAY PANEL - 135 mg Tablet Bottle Label

SOLODYN 
minocycline hydrochloride   tablet, film coated, extended release
Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)99207-460
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
minocycline hydrochloride (minocycline) minocycline45 mg
Inactive Ingredients
Ingredient NameStrength
lactose monohydrate 
hypromellose 2910 (50 cps) 
titanium dioxide 
triacetin 
ferrosoferric oxide 
Product Characteristics
ColorGRAYScore no score
ShapeOVALSize16mm
FlavorImprint Code DYN;045
Contains    
Packaging
#NDCPackage DescriptionMultilevel Packaging
199207-460-3030 TABLET In 1 BOTTLENone
299207-460-10100 TABLET In 1 BOTTLENone
399207-460-0120 BLISTER PACK In 1 CARTONcontains a BLISTER PACK
31 TABLET In 1 BLISTER PACKThis package is contained within the CARTON (99207-460-01)

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05080805/08/2006

SOLODYN 
minocycline hydrochloride   tablet, film coated, extended release
Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)99207-463
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
minocycline hydrochloride (minocycline) minocycline65 mg
Inactive Ingredients
Ingredient NameStrength
hypromellose 2910 (50 cps) 
lactose monohydrate 
FD&C BLUE NO. 1 
polyethylene glycol 3350 
FD&C BLUE NO. 2 
titanium dioxide 
D&C YELLOW NO. 10 
Product Characteristics
ColorBLUEScore no score
ShapeOVALSize16mm
FlavorImprint Code DYN;065
Contains    
Packaging
#NDCPackage DescriptionMultilevel Packaging
199207-463-3030 TABLET In 1 BOTTLENone
299207-463-0120 BLISTER PACK In 1 CARTONcontains a BLISTER PACK
21 TABLET In 1 BLISTER PACKThis package is contained within the CARTON (99207-463-01)

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05080807/23/2009

SOLODYN 
minocycline hydrochloride   tablet, film coated, extended release
Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)99207-461
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
minocycline hydrochloride (minocycline) minocycline90 mg
Inactive Ingredients
Ingredient NameStrength
hypromellose 2910 (50 cps) 
lactose monohydrate 
titanium dioxide 
ferric oxide yellow 
polyethylene glycol 3350 
triacetin 
Product Characteristics
ColorYELLOWScore no score
ShapeOVALSize16mm
FlavorImprint Code DYN;090
Contains    
Packaging
#NDCPackage DescriptionMultilevel Packaging
199207-461-3030 TABLET In 1 BOTTLENone
299207-461-10100 TABLET In 1 BOTTLENone
399207-461-0120 BLISTER PACK In 1 CARTONcontains a BLISTER PACK
31 TABLET In 1 BLISTER PACKThis package is contained within the CARTON (99207-461-01)

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05080805/08/2006

SOLODYN 
minocycline hydrochloride   tablet, film coated, extended release
Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)99207-464
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
minocycline hydrochloride (minocycline) minocycline115 mg
Inactive Ingredients
Ingredient NameStrength
hypromellose 2910 (50 cps) 
lactose monohydrate 
D&C YELLOW NO. 10 
triacetin 
FD&C BLUE NO. 1 
titanium dioxide 
FD&C BLUE NO. 2 
Product Characteristics
ColorGREENScore no score
ShapeOVALSize16mm
FlavorImprint Code DYN;115
Contains    
Packaging
#NDCPackage DescriptionMultilevel Packaging
199207-464-3030 TABLET In 1 BOTTLENone
299207-464-0120 BLISTER PACK In 1 CARTONcontains a BLISTER PACK
21 TABLET In 1 BLISTER PACKThis package is contained within the CARTON (99207-464-01)

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05080807/23/2009

SOLODYN 
minocycline hydrochloride   tablet, film coated, extended release
Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)99207-462
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
minocycline hydrochloride (minocycline) minocycline135 mg
Inactive Ingredients
Ingredient NameStrength
hypromellose 2910 (50 cps) 
lactose monohydrate 
titanium dioxide 
polyethylene glycol 3350 
ferric oxide red 
triacetin 
Product Characteristics
ColorPINK (orange-brown) Score no score
ShapeOVALSize16mm
FlavorImprint Code DYN;135
Contains    
Packaging
#NDCPackage DescriptionMultilevel Packaging
199207-462-3030 TABLET In 1 BOTTLENone
299207-462-10100 TABLET In 1 BOTTLENone
399207-462-0120 BLISTER PACK In 1 CARTONcontains a BLISTER PACK
31 TABLET In 1 BLISTER PACKThis package is contained within the CARTON (99207-462-01)

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05080805/08/2006

Labeler - Medicis Pharmaceutical Corp. (182837492)
Establishment
NameAddressID/FEIOperations
WellSpring Pharmaceutical Canada Corp.251086799MANUFACTURE
Establishment
NameAddressID/FEIOperations
Sharp Corp.002346625MANUFACTURE
Establishment
NameAddressID/FEIOperations
AAIPharma Services037149663MANUFACTURE
Revised: 12/2009Medicis Pharmaceutical Corp.